DTPA (Diethylenetriaminepenta-acetate) Chelation for Symptoms After Gadolinium-assisted MRI Exposure
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The study aims at gathering additional data on the safety and effectiveness of using
intravenous administration of the drugs Ca-DTPA/Zn-DTPA to remove the heavy metal gadolinium
from the bodies of patients who have retained it and developed symptoms of Gadolinium
Deposition Disease following an MRI in which a gadolinium-containing contrast agent was
utilized. The outcome data will include measures of symptom relief after as many as six
paired Calcium-DTPA/Zinc-DTPA chelation treatments. The study also aims at gathering
additional data before and after DTPA treatment regarding levels of certain cytokines in the
patients' blood that have been reported to be abnormally elevated in patients with retained
gadolinium.